| 2021 | KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma
| FUTURE ONCOLOGY |
| 2015 | Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme
| PLOS ONE |
| 2019 | Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study | LANCET ONCOLOGY |
| 2023 | Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study | LUNG CANCER |
| 2023 | Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301 | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
| JOURNAL OF THORACIC ONCOLOGY |
| 2022 | Lazertinib: on the Way to Its Throne
| YONSEI MEDICAL JOURNAL |
| 2019 | LBA4 - Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the Phase 3 MYSTIC study | ANNALS OF ONCOLOGY |
| 2022 | Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC
| JTO Clinical and Research Reports |
| 2020 | Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2011 | Lung cancer in never smokers: change of a mindset in the molecular era. | LUNG CANCER |
| 2022 | Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy | RADIOTHERAPY AND ONCOLOGY |
| 2023 | Management of HER2 alterations in non-small cell lung cancer - The past, present, and future | LUNG CANCER |
| 2023 | Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study
| LUNG CANCER |
| 2022 | MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer | FUTURE ONCOLOGY |
| 2018 | Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors | ANNALS OF ONCOLOGY |
| 2021 | Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma
| CLINICAL CANCER RESEARCH |
| 2019 | Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing
| PLOS ONE |
| 2019 | Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer | CLINICAL LUNG CANCER |
| 2022 | Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2020 | Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
| BRITISH JOURNAL OF CANCER |
| 2020 | Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
| BRITISH JOURNAL OF CANCER |
| 2011 | Multiple target loci assembly sequencing (mTAS). | ANALYTICAL BIOCHEMISTRY |
| 2015 | Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance
| GENOME MEDICINE |
| 2019 | Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate
| PLOS ONE |
| 2016 | Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer | LUNG CANCER |
| 2017 | Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs | LUNG CANCER |
| 2016 | Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
| ONCOTARGET |
| 2018 | Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
| LUNG CANCER |
| 2015 | Nivolumab in NSCLC: latest evidence and clinical potential | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2019 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | LANCET ONCOLOGY |
| 2005 | Nodal stage-oriented adjuvant chemotherapy in breast cancer
| Thesis |
| 2019 | NOVA1 induction by inflammation and NOVA1 suppression by epigenetic regulation in head and neck squamous cell carcinoma
| Scientific Reports |
| 2022 | Novel allosteric glutaminase 1 inhibitors with macrocyclic structure activity relationship analysis
| BIOORGANIC & MEDICINAL CHEMISTRY LETTERS |
| 2021 | Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study | CANCER |
| 2017 | Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition | ONCOGENE |
| 2017 | Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. | JOURNAL OF CLINICAL ONCOLOGY |
| 2017 | Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective
| CANCER RESEARCH AND TREATMENT |
| 2017 | Optimal dose and volume for postoperative radiotherapy in brain oligometastases from lung cancer: a retrospective study
| RADIATION ONCOLOGY JOURNAL |
| 2023 | Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON
| CANCER DISCOVERY |
| 2020 | Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
| CANCER RESEARCH AND TREATMENT |
| 2018 | Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2022 | Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial | JOURNAL OF THORACIC ONCOLOGY |
| 2020 | Osimertinib Plus Savolitinib in Patients With EGFR Mutation-Positive, MET-amplified, Non-Small-Cell Lung Cancer After Progression on EGFR Tyrosine Kinase Inhibitors: Interim Results From a Multicentre, Open-Label, Phase 1b Study | LANCET ONCOLOGY |
| 2019 | Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset | JOURNAL OF THORACIC ONCOLOGY |
| 2020 | Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I | MOLECULAR CANCER THERAPEUTICS |
| 2020 | Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial | ANNALS OF ONCOLOGY |
| 2018 | Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEW ENGLAND JOURNAL OF MEDICINE |
| 2019 | Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma
| SCIENTIFIC REPORTS |
| 2020 | Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
| EUROPEAN JOURNAL OF CANCER |
| 2019 | Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study | LANCET ONCOLOGY |
| 2021 | Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC)
| CLINICAL LUNG CANCER |
| 2023 | Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
| LUNG CANCER |
| 2022 | Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC | CANCER DISCOVERY |
| 2016 | PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
| SCIENTIFIC REPORTS |
| 2021 | Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study | LANCET |
| 2019 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial | Lancet |
| 2020 | Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer
| SCIENTIFIC REPORTS |
